# Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

> **NCT00568594** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 176 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** APL180
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00568594
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-09
- **Final completion:** —
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568594, "Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00568594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*